210 related articles for article (PubMed ID: 19508658)
1. Resource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a Medicaid population.
Yu AP; Atanasov P; Ben-Hamadi R; Birnbaum H; Stensland MD; Philips G
Value Health; 2009; 12(5):708-15. PubMed ID: 19508658
[TBL] [Abstract][Full Text] [Related]
2. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT
Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
[TBL] [Abstract][Full Text] [Related]
3. Comparing the treatment patterns of patients with schizophrenia treated with olanzapine and quetiapine in the Pennsylvania Medicaid population.
Yu AP; Ben-Hamadi R; Birnbaum HG; Atanasov P; Stensland MD; Philips G
Curr Med Res Opin; 2009 Mar; 25(3):755-64. PubMed ID: 19199435
[TBL] [Abstract][Full Text] [Related]
4. Cost of antipsychotic polypharmacy in the treatment of schizophrenia.
Zhu B; Ascher-Svanum H; Faries DE; Correll CU; Kane JM
BMC Psychiatry; 2008 Apr; 8():19. PubMed ID: 18394168
[TBL] [Abstract][Full Text] [Related]
5. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
Jing Y; Kim E; You M; Pikalov A; Tran QV
J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195
[TBL] [Abstract][Full Text] [Related]
6. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
Kongsakon R; Leelahanaj T; Price N; Birinyi-Strachan L; Davey P
J Med Assoc Thai; 2005 Sep; 88(9):1267-77. PubMed ID: 16536115
[TBL] [Abstract][Full Text] [Related]
7. Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder.
Jing Y; Johnston SS; Fowler R; Bates JA; Forbes RA; Hebden T
J Med Econ; 2011; 14(6):777-86. PubMed ID: 21954966
[TBL] [Abstract][Full Text] [Related]
8. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.
Gibson PJ; Damler R; Jackson EA; Wilder T; Ramsey JL
Value Health; 2004; 7(1):22-35. PubMed ID: 14720128
[TBL] [Abstract][Full Text] [Related]
9. Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
Yan T; Greene M; Chang E; Houle CR; Waters HC; Tarbox MH; Broder MS
Clin Ther; 2020 Jan; 42(1):77-93. PubMed ID: 31928831
[TBL] [Abstract][Full Text] [Related]
10. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China.
Yang L; Li M; Tao LB; Zhang M; Nicholl MD; Dong P
Value Health; 2009; 12 Suppl 3():S66-9. PubMed ID: 20586985
[TBL] [Abstract][Full Text] [Related]
12. Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients--a cost analysis.
Law WL; Hui HY; Young WM; You JH
Int J Clin Pharmacol Ther; 2007 May; 45(5):264-70. PubMed ID: 17542348
[TBL] [Abstract][Full Text] [Related]
13. The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia.
Chen L; McCombs JS; Park J
Value Health; 2008; 11(1):34-43. PubMed ID: 18237358
[TBL] [Abstract][Full Text] [Related]
14. Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine.
Gianfrancesco F; Pesa J; Wang RH
J Manag Care Pharm; 2005 Apr; 11(3):220-30. PubMed ID: 15804206
[TBL] [Abstract][Full Text] [Related]
15. Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders.
Kopala L; Smith G; Malla A; Williams R; Love L; Talling D; Balshaw R
Acta Psychiatr Scand Suppl; 2006; (430):29-39. PubMed ID: 16542323
[TBL] [Abstract][Full Text] [Related]
16. Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.
Rascati KL; Johnsrud MT; Crismon ML; Lage MJ; Barber BL
Pharmacoeconomics; 2003; 21(10):683-97. PubMed ID: 12828491
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns, healthcare resource utilization and costs in patients with bipolar disorder, newly treated with extended release or immediate release quetiapine fumarate using US healthcare administrative claims data.
Locklear JC; Alemayehu B; Brody RS; Chavoshi S; Tunceli O; Kern D; Earley WR
Clin Ther; 2013 Dec; 35(12):1923-32. PubMed ID: 24275622
[TBL] [Abstract][Full Text] [Related]
18. Intent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depression.
Jing Y; Kalsekar I; Curkendall SM; Carls GS; Bagalman E; Forbes RA; Hebden T; Thase ME
Clin Ther; 2011 Sep; 33(9):1246-57. PubMed ID: 21840058
[TBL] [Abstract][Full Text] [Related]
19. One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis.
Kim E; You M; Pikalov A; Van-Tran Q; Jing Y
BMC Psychiatry; 2011 Jan; 11():6. PubMed ID: 21214937
[TBL] [Abstract][Full Text] [Related]
20. Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia.
Zhao Z
Curr Med Res Opin; 2004 Jul; 20(7):1039-48. PubMed ID: 15265249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]